Advertisement
The American Journal of Cardiology®
Advanced SearchSave search
Full length article| Volume 86, ISSUE 12, SUPPLEMENT 1, 15-18, December 21, 2000

Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy

  • Marianne J Legato
    Correspondence
    Address for reprints: Marianne J. Legato, MD, Partnership for Women’s Health, 14 East 60th Street, PH Floor, New York, New York 10022
    Affiliations
    Columbia University College of Physicians and Surgeons, New York, New York, USA
    Search for articles by this author
DOI:https://doi.org/10.1016/S0002-9149(00)01463-6
Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy
Previous ArticleThe epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease
Next ArticleHigh-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from framingham to the veterans affairs high-density lipoprotein intervention trial

      Abstract

      Cardiovascular disease, which kills more US women than all cancers combined, may pose an even greater risk for women than for men. For example, the risk factors, testing modalities, presenting symptoms and the therapeutic choices made for women with coronary artery disease are significantly different from those for men. Low levels of high-density lipoprotein cholesterol (HDL-C), <35 mg/dL in men and <45 mg/dL in women, is associated with a greater risk of coronary artery disease and more progression of angiographically demonstrated disease in women, while increasing HDL-C has a more cardioprotective effect in the female than in the male population. The total cholesterol-to-HDL-C ratio is also more predictive of coronary artery disease in women than in men. Because average HDL-C levels in women are approximately 10 mg/dL higher than in men, target HDL-C should be higher (>45 mg/dL) in women. This is not yet reflected in clinical guidelines. Diabetes is particularly hazardous in women, and low HDL-C levels constitute a disproportionate risk for coronary artery disease in diabetic women compared with diabetic men. Regrettably, although lipid-lowering drugs have been shown to be effective in women, they are more rarely prescribed for women than for men.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. AHA Heart and Stroke Guide: Women, Heart Disease, and Stroke Statistics. www.americanheart.org.

        View in Article
        • Kannel W.B
        Contributions of the Framingham Study to the conquest of coronary artery disease.
        Am J Cardiol. 1988; 62: 1109-1112
        View in Article

      3. Abbott RD, Wilson PWF, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis 1988;8:207–211.

        View in Article
        • Pearson T.A
        • Bulkley B.H
        • Achuff S.C
        • Kwiterovich P.O
        • Gordis L
        The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease.
        Am J Epidemiol. 1979; 109: 285-295
        View in Article
        • Gordon D.J
        • Probstfield J.L
        • Garrison R.J
        • Neaton J.D
        • Castelli W.P
        • Knoke J.D
        • Jacobs Jr, D.R
        • Bangdiwala S
        • Tyroler H.A
        High-density lipoprotein cholesterol and cardiovascular disease.
        Circulation. 1989; 79: 8-15
        View in Article
        • Miller M
        • Mead L.A
        • Kwiterovich Jr, P.O
        • Pearson T.A
        Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease.
        Am J Cardiol. 1990; 65: 1-5
        View in Article

      7. Barnard RJ. Effects of life-style modification on serum lipids. Arch Intern Med 1991l;151:1389–1394.

        View in Article
        • Lewis S.J
        • Sacks F.M
        • Mitchell J.S
        • East C
        • Glasser S
        • Kell S
        • Letterer R
        • Limacher M
        • Moye L.A
        • Rouleau J.L
        • Pfeffer M.A
        • Braunwald E
        Effect of pravastatin on cardiovascular events in women after myocardial infarction.
        J Am Coll Cardiol. 1998; 32: 140-146
        View in Article
        • Miettinen T.A
        • Pyorala K
        • Olsson A.G
        • Musliner T.A
        • Cook T.J
        • Faergemoan O
        • Berg K
        • Pedersen T
        • Kjekshus J
        Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris.
        Circulation. 1997; 96: 4211-4218
        View in Article
        • Knopp R.H
        • Ginsberg J
        • Albers J.J
        • Hoff C
        • Ogilvie J.T
        • Warmick G.R
        • Burrows E
        • Retzlaff B
        • Poole M
        Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects.
        Metabolism. 1985; 34: 642-650
        View in Article

      11. Niaspan patient information Package Insert. Kos Pharmaceuticals, 1998.

        View in Article
        • Sueta C
        • Chowdhury M
        • Boccuzzi S.J
        • Smith Jr, S.C
        • Alexander C.M
        • Londhe A
        • Lulla A
        • Simpson Jr, R.J
        Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.
        Am J Cardiol. 1999; 83: 1303-1307
        View in Article

      13. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD, for the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000;160:343–347.

        View in Article

      14. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Jama 1995;273:199–208.

        View in Article

      15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary artery disease in postmenopausal women. Jama 1998;280:605–613.

        View in Article

      16. Sbarouni E, Kyriakides ZS, Kremastinos DTh. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of cholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;32:1244–1250.

        View in Article
        • Walsh B.W
        • Kuller L.H
        • Wild R.A
        • Paul S
        • Farmer M
        • Lawrence J.B
        • Shah A.S
        • Anderson P.W
        Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women (see comments).
        Jama. 1998; 279: 1445-1451
        View in Article

      Article Info

      Identification

      DOI: https://doi.org/10.1016/S0002-9149(00)01463-6

      Copyright

      © 2000 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX